Trasylol licence suspended

The licence for Trasylol (aprotinin) has been suspended on the advice of the Commission on Human Medicines (CHM). Global marketing of the drug had already been suspended voluntarily by the marketing authorisation holders (Bayer plc and Nordic Pharma) due to safety concerns.

The CHM decision to suspend the licence was made on the basis of preliminary findings from a clinical trial (the BART study), which was stopped early after excess mortality was observed in the aprotinin arm compared with the tranexamic acid and aminocaproic acid arms (relative risk 1.5).


In addition, data from observational studies suggested an increased risk of mortality as well as an increased risk of cardiac, cerebrovascular and renal effects.


Trasylol is indicated for the reduction of blood loss and need for blood transfusion in coronary artery bypass graft surgery.


The CHM concluded that although aprotinin may be more effective than the comparator drugs at reducing bleeding, the risks outweigh the benefits.

 

Further information: Bayer 01635 563000 and/or MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...

Proposed withdrawal of bipolar disorder treatment revoked

Proposed withdrawal of bipolar disorder treatment revoked

The manufacturer of first-line bipolar disorder treatment...